CLINICAL SAFETY AND EFFICACY OF TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM CAPSULES COMBINED WITH CHEMORADIOTHERAPY IN TREATING ADVANCED LUNG SQUAMOUS CELL CARCINOMA

Yana Wei¹, Qing Wei^{2, *}

¹Department of Oncology, The Second Ward, The People’s Hospital of Hechi, Hechi, Guangxi 547000, China - ²Department of Respiratory and Critical Care Medicine, The People’s Hospital of Hechi, Hechi, Guangxi 547000, China

Introduction: To clarify clinical safety and efficacy of Tegafur,Gimeracil and Oteracil Potassium Capsules combined with chemoradiotherapy in treating advanced lung squamous cell carcinoma (LSCC).

Materials and Methods: A total of 80 advanced LSCC patients treated in our hospital from JJuly 2019 to December 2021 were chosen and randomly divided into two groups with 40 cases each group. The control group received treatment with chemotherapy alone, and the observation group received treatment with Tegafur,Gimeracil and Oteracil Potassium Capsules combined with cisplatin on the basis of the control group. The clinical efficacy, adverse reactions, quality of life scores, tumor markers and survival rate in both groups were compared and analyzed.

Results: The total effective rate and disease control rate presented statistical significance between two groups (P<0.05). After treatment, KPS scores in both groups presented elevation relative to those before treatment, and KPS scores in the observation group presented elevation relative to those in the control group, with statistical significance (P<0.05). After treatment, CEA, NSE, SCC, and VEGF levels in both groups presented depletion, and indicators in the observation group presented depletion relative to those in the control group, with statistical significance (P<0.05). The incidence of adverse reactions in the observation group presented depletion relative to that in the control group, with statistical significance (P<0.05). The 3-year survival rate in observation group presented elevation relative to that in the control group, with statistical significance (P<0.05).

Conclusion: The application of Tegafur,Gimeracil and Oteracil Potassium Capsules in treating advanced LSCC patients has a positive clinical efficacy, and toxic and side effects can be tolerated, with high safety, and it markedly elevates quality of life of patients, which is worthy of promotion and application in clinical practice.